Table 4

Baseline and 3-month and 6-month tocilizumab therapy evaluation criteria in eight patients with peripheral spondyloarthritis

Patient 14

Patient 15

Patient 16

Patient 17

Patient 18

Patient 19

Patient 20

Patient 21


DAS28

M0

4.02

4.52

5

4.58

5.41

6.2

5.23

4.92

M3 (absolute value)

2.82

3.85

4.3

2.88

3.18

1.1

5.1

4.70

M3 EULAR response (yes/no)

Yes (good)

No

Yes (moderate)

Yes (good)

Yes (good)

Yes (remission)

No

No

M6 (absolute value)

1.95

4.01

5.34

3.12

NA

NA

NA

NA

M6 EULAR response (yes/no)

Yes (remission)

No

No

Yes (good)

NA

NA

NA

NA

ASDAS

M0

2.41

4.03

MD

MD

MD

3.8

3

MD

M3 (absolute value)

1.50

2.64

MD

MD

MD

1.35

3.1

MD

M6 (absolute value)

1.03

2.79

MD

MD

MD

NA

NA

MD

SJCa

M0

7

2

2

0

3

9

4

7

M3 (absolute value)

NA

NA

NA

NA

7

0

3

6

M6 (absolute value)

0

6

1

0

NA

NA

NA

NA

TJCa

M0

7

6

5

5

0

15

7

12

M3 (absolute value)

NA

NA

NA

NA

0

0

6

11

M6 (absolute value)

2

4

3

8

NA

NA

NA

NA

BASDAI, 0 to 100

M0

42

75

NA

79.4

67

48

4.7

NA

M3 (change from M0; %)

-31

-6.7

NA

-9

+6

NA

-2.1

NA

M6 (change from M0; %)

-59.5

-4.7

NA

-32

NA

NA

NA

NA

BASFI, 0 to 100

M0

40

72

MD

MD

54

70

NA

NA

M3 (change from M0, %)

-17.5

-26

MD

MD

+44

NA

NA

NA

M6 (change from M0, %)

-12.5

-12.5

MD

MD

NA

NA

NA

NA

Pain VAS, 0 to 10

M0

1.5

7

5

7

7

5

6

8

M3 (absolute value)

2

8

NA

6

8

1

6.5

6

M6 (absolute value)

1

9

6

7.5

NA

NA

NA

NA

PGA, 0 to 10

M0

1

6

7

7.5

7

5.2

6.5

8

M3 (absolute value)

3.5

6

MD

MD

7

1

6.5

8

M6 (absolute value)

1.2

6

8

MD

NA

NA

NA

NA

CRP (mg/dl)a

M0

20.2

17

119

12

112.3

65

4

1

M3 (absolute value)

NA

NA

NA

NA

9.5

1

5

1

M6 (absolute value)

0.4

0.8

128

1

NA

NA

NA

NA

ESR (mm)a

M0

39

22

67

26

103

60

27

7

M3 (absolute value)

NA

NA

NA

NA

8

4

7

8

M6 (absolute value)

5

7

70

2

NA

NA

NA

NA


ASDAS, Assessment of SpondyloArthritis International Society endorsed disease activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; M0, month 0 (baseline); M3, month 3; M6, month 6; NA, not available; MD, missing data; PGA, patient's global assessment of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. aFor SJC, TJC, CRP, and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6).

Lekpa et al. Arthritis Research & Therapy 2012 14:R53   doi:10.1186/ar3766

Open Data